Share prices for Abiomed Inc. stock slipped today on news that the FDA warned the company about marketing a version of its Impella heart pump using un-approved claims.
Shares of Abiomed Inc. (NSDQ:ABMD) slipped nearly five percent on Wall Street this morning, after the FDA posted a warning letter admonishing the heart pump maker for marketing a device for uses it's not cleared for.
The federal watchdog agency said a May 12 review of Danvers, Mass.-based Abiomed's advertising, product labels and website "indicate that Abiomed is making claims that we stated were inappropriate in a January 28, 2010, letter to your firm" about its Impella Recover LP 2.5 cardiac assist device.
"These claims represent a major modification to both the intended use and the indications for use of the device," according to the missive.
Abiomed spokeswoman Aimee Maillet told MassDevice that the FDA's letter addresses promotional materials the company used last year and has since dropped.
"We are working with the FDA to address the issues, but have since ceased the specific promotional items from 2010," Maillet wrote in an email. "We are working with the FDA to ensure all of our promotional materials comply with the agency moving forward."
Abiomed won 510(k) clearance for the device, which is inserted via catheter into the heart to help it function, "for 'partial circulatory support using an extracorporeal bypass control unit, for periods up to 6 hours. It is also intended to be used to provide partial circulatory support (for periods up to 6 hours) during procedures not requiring cardiopulmonary bypass. The Impella Recover LP 2.5 also provides pressure measurements which are useful in determining intravascular pressure,'" according to the FDA.
But the company touted the device for uses outside that clearance, specifically for comparing the Impella to treatment with an intra-aortic balloon pump, which the agency said it warned Abiomed not to do in the January letter.
Imris says it filed for Chapter 11 bankruptcy protection, with a bailout offer from Deerfield...
Penumbra says it won 510(k) clearance from the FDA for its Ace64 intra-arterial stent.
The FDA labels as Class I CareFusion's recall of its Avea ventilators over a possibly fatal...
Small medtech companies are finding value in outsourcing their research & development functions,...